Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Assets (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Assets for 16 consecutive years, with $78.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets fell 40.57% to $78.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $78.0 million, a 40.57% decrease, with the full-year FY2024 number at $126.6 million, down 7.81% from a year prior.
  • Assets was $78.0 million for Q3 2025 at Harvard Bioscience, down from $80.1 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $162.3 million in Q4 2021 to a low of $78.0 million in Q3 2025.
  • A 5-year average of $134.2 million and a median of $142.9 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: increased 4.49% in 2022, then plummeted 40.57% in 2025.
  • Harvard Bioscience's Assets stood at $162.3 million in 2021, then decreased by 10.46% to $145.4 million in 2022, then fell by 5.5% to $137.4 million in 2023, then decreased by 7.81% to $126.6 million in 2024, then plummeted by 38.42% to $78.0 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Assets are $78.0 million (Q3 2025), $80.1 million (Q2 2025), and $79.8 million (Q1 2025).